glp 1 advantage book Noom Bets Its Behavior Change Roots Can Win the GLP-1 Wars GLP-1 Agonists in Transplant Patients:

Chronic exposure to trace pharmaceutical residues has been associated with cancer, hormonal imbalances, neurological disorders, and developmental abnormalities

The honest steelman argument for BPC-157 advocates is this: some peer-reviewed animal research does show real regenerative effects, and the argument that we need more human trials is easier said than done when the FDA itself controls the pathway to those trials

To date several clinical trials have been conducted to test IGF-1 under several conditions and an infinity of animal models have been used to investigate its deficiency, treatment and to exploit its actions

Multiple GLP-1R agonists have entered into clinical trials, such as semaglutide, progressing to approval